预约演示
更新于：2026-09-23
Isotretinoin
异维A酸
更新于：2026-09-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1982-05-07), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C20H28O2 |
InChIKeySHGAZHPCJJPHSC-XFYACQKRSA-N |
CAS号4759-48-2 |
关联
259
项与 异维A酸 相关的临床试验NCT07675239
Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety, and Cure Rate in Adult Patients With Tinea Corporis/Cruris: A Randomized Controlled Trial.
ChiCTR2600132301
A Dual-Center, Prospective, Exploratory Study of Vunakizumab, an IL-17A Inhibitor, for the Treatment of Acne Fulminans
NCT07629167
A Phase 2 Study of Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
100 项与 异维A酸 相关的临床结果
登录后查看更多信息
100 项与 异维A酸 相关的转化医学
登录后查看更多信息
100 项与 异维A酸 相关的专利（医药）
登录后查看更多信息
5,939
项与 异维A酸 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Experts’ view on the management of scalp seborrheic dermatitis in Italy
Review
作者: Guida, Stefania ; Caldarola, Giacomo ; Micali, Giuseppe ; Fulgione, Elisabetta ; Piraccini, Bianca Maria
BACKGROUND:
Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes.
OBJECTIVES AND METHODS:
This study aimed to develop a practical algorithm for SSD management in Italy, by gathering insights from Italian dermatology experts on diagnosis, treatment and long-term management of SSD.
RESULTS:
According to literature review and clinical experience, accurate diagnosis of SSD requires medical history, clinical evaluation, disease severity assessment and trichoscopy. The differentiation of SSD from psoriasis, eczema, and tinea capitis is essential to guide appropriate treatment, which should counteract the main pathogenic mechanisms underlying the disease and be tailored to the severity of clinical manifestations. Topical antifungals are the first-line treatments due to their efficacy in reducing Malassezia colonization. The use of topical anti-inflammatory agents, including corticosteroids, is useful for moderate-to-severe cases, but should be limited due to potential adverse effects. Selenium disulfide may be a useful option for both acute symptom control and long-term maintenance because of its antifungal, sebostatic, keratolytic, and microbiome-restoring properties, associated with a high degree of patient satisfaction. Systemic antifungals may be considered in refractory cases.
CONCLUSION:
This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Sociodemographic, clinical, and behavioral determinants of treatment adherence in acne vulgaris: a multicenter study
Article
作者: Ferhatosmanoğlu, Arzu ; Tosun, Mustafa ; İlhan Erdil, Dilara ; Kalkan, Göknur ; Akpınar Kara, Yeşim ; Kaya Özden, Hatice ; Afacan Yıldırım, Elif ; İnan Yüksel, Esma ; Arıca, İbrahim Etem ; Başara Şahin, Rana ; Tümtürk, Mustafa ; Yıldırım, Mehmet ; Külcü Çakmak, Seray ; Canat, Harbiye Dilek ; Bal Avcı, Elif ; Meral, Elif Nur ; Polat, Mualla ; Yıldırım, Yasemin Aygül ; Kartal, Selda Pelin ; Aksoy Saraç, Gülhan ; Karadağ, Ayşe Serap
BACKGROUND:
This multicenter study aimed to evaluate treatment adherence and satisfaction among patients with acne vulgaris.
METHODS:
A total of 2,349 patients from 18 dermatology centers across Türkiye completed structured questionnaires.
RESULTS:
The participants were predominantly female (79.4%) with a mean age of 21.6 years. Overall, 48% reported consistent adherence to therapy, with significantly lower adherence among males (p < 0.001). The most frequent reasons for nonadherence were forgetfulness (28.7%), dislike of the treatment (26.4%), and reluctance to maintain long-term therapy (21.5%). Treatment adherence was positively associated with higher educational levels (p = 0.006) and greater acne severity (p < 0.001). Logistic regression revealed that systemic oral therapy (OR = 4.37, 95% CI: 3.147-6.086; p < 0.001) and oral isotretinoin (OR = 4.81, 95% CI: 3.379-6.869; p < 0.001) significantly increased adherence compared to topical therapy. Oral treatment was also independently associated with greater satisfaction (OR = 2.33, 95% CI: 1.767-3.095; p < 0.001). Moreover, mild acne severity (OR = 1.67, 95% CI: 1.216-2.297; p = 0.002) and older age (per year; OR = 1.05, 95% CI: 1.020-1.088; p = 0.001) predicted higher satisfaction.
CONCLUSION:
Systemic therapies-particularly oral isotretinoin-were associated with improved adherence and satisfaction.
2026-09-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Isotretinoin-Induced Meibomian Gland Dysfunction: Rationale for Proactive Clinical Surveillance
Review
作者: Sánchez-Ventosa, Álvaro ; Palacín-Miranda, Elisa ; Villalba-González, Marta ; López-Pérez, M. Dolores ; Gersól-Pérez-Angulo, Javier ; Cano-Ortiz, Antonio ; Villarrubia-Cuadrado, Alberto ; Díaz-Ramos, José-Carlos ; Prados-Carmona, Álvaro ; Prados-Carmona, Juan J.
Purpose::
We synthesized the current evidence on isotretinoin-induced Meibomian gland dysfunction (MGD), including underlying mechanisms, clinical manifestations, risk factors, management strategies, and the need for updated screening recommendations.
Methods::
The review was conducted during November 2025, covering multiple databases including Semantic Scholar, PubMed, and others. The search yielded 1,046 records; after eligibility assessment, 53 studies were included. Clinical, preclinical, and review articles, as well as clinical guidelines were considered if they met predefined quality standards.
Results::
Isotretinoin significantly impairs Meibomian gland function by suppressing PPARγ signalling, leading to reduced lipid secretion, glandular inflammation, and atrophy. These effects often precede overt symptoms, complicating early diagnosis. Risk factors include prolonged or high-dose therapy, pre-existing ocular surface disease, contact lens wear, and dermatologic or systemic comorbidities. Clinical manifestations range from mild dry eye symptoms to persistent ocular surface damage. Current management is largely palliative, and there is no validated therapy for reversing gland atrophy. Despite mounting evidence, existing clinical guidelines do not recommend ophthalmologic screening, potentially delaying diagnosis and intervention.
Conclusion::
Isotretinoin-induced MGD is a clinically significant and underrecognized adverse effect. The absence of routine ophthalmological screening and standardized monitoring protocols leaves high-risk patients vulnerable to irreversible gland damage. Proactive surveillance, structured prevention, and individualized management are essential to minimize long-term ocular complications. Among all strategies, infrared meibography may serve as an objective, non-invasive tool to monitor isotretinoin-induced Meibomian gland damage, guiding early intervention and treatment decisions. Further research is needed to establish optimal screening strategies and explore effective preventive and restorative therapies.
100 项与 异维A酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经母细胞瘤 | 日本 | 2026-06-19 | |
| 寻常痤疮 | 加拿大 | 2023-06-22 | |
| 囊性痤疮 | 澳大利亚 | 1994-12-05 | |
| 痤疮样疹 | 美国 | 1982-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体隐性鱼鳞病 | 临床3期 | 美国 | 2022-06-21 | |
| 常染色体隐性鱼鳞病 | 临床3期 | 加拿大 | 2022-06-21 | |
| 常染色体隐性鱼鳞病 | 临床3期 | 法国 | 2022-06-21 | |
| 常染色体隐性鱼鳞病 | 临床3期 | 德国 | 2022-06-21 | |
| 常染色体隐性鱼鳞病 | 临床3期 | 意大利 | 2022-06-21 | |
| X联锁鱼鳞病 | 临床3期 | 美国 | 2022-06-21 | |
| X联锁鱼鳞病 | 临床3期 | 加拿大 | 2022-06-21 | |
| X联锁鱼鳞病 | 临床3期 | 法国 | 2022-06-21 | |
| X联锁鱼鳞病 | 临床3期 | 德国 | 2022-06-21 | |
| X联锁鱼鳞病 | 临床3期 | 意大利 | 2022-06-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 37 | (Inflammatory Bowel Disease) | 夢鏇壓糧鹽遞憲範築艱(鬱艱廠選鹽鑰網夢襯憲) = 獵鏇憲鹽鑰壓鏇艱獵廠 鏇膚獵顧製簾淵襯淵簾 (糧鏇鹹簾獵鹹構顧簾觸 ) 更多 | 积极 | 2026-05-02 | ||
N/A | 23,760 | 鏇鬱憲製衊遞艱網窪構(遞淵鹹淵選構獵積願選) = 夢憲蓋齋構夢廠鹽遞糧 蓋廠窪積網選鏇鹹願襯 (醖衊築膚壓衊鹽繭遞齋, 14.0) 更多 | 不佳 | 2026-03-27 | |||
N/A | 764 | Oral Isotretinoin + H9-antihistamines | 衊淵齋繭鹹糧積鹹築壓(獵觸鹽願遞獵齋夢觸襯): RR = 0.83 (95.0% CI, 0.69 ~ 0.99), P-Value = 0.04 | 积极 | 2026-03-27 | ||
N/A | 120 | 鑰淵鹹糧鹹繭襯築簾餘(淵廠齋鬱鏇鏇範簾衊製) = 衊夢構積窪積壓選繭淵 繭範鏇鹽積觸鏇夢構齋 (鹽願夢鹽醖範窪鬱獵選 ) 更多 | 积极 | 2026-03-27 | |||
N/A | 1,658 | Traditional isotretinoin | 範憲繭製糧糧構鹽願網(壓築鹹製糧醖構窪積構) = 廠簾網鑰壓鬱製觸夢壓 淵齋鏇醖餘顧獵願淵餘 (製繭窪遞齋築築憲憲蓋 ) | 积极 | 2026-03-27 | ||
Intermittent isotretinoin | 範憲繭製糧糧構鹽願網(壓築鹹製糧醖構窪積構) = 鑰膚齋遞遞淵鏇獵顧夢 淵齋鏇醖餘顧獵願淵餘 (製繭窪遞齋築築憲憲蓋 ) | ||||||
N/A | 1,338 | 遞遞構繭積齋製鬱糧蓋(齋壓鑰淵壓繭遞顧衊窪) = 憲壓淵膚憲餘顧鹽艱製 餘築襯鹽築蓋構顧願鬱 (艱獵襯艱淵網醖網鬱衊 ) | 积极 | 2026-03-27 | |||
Topical monotherapy | 遞遞構繭積齋製鬱糧蓋(齋壓鑰淵壓繭遞顧衊窪) = 鑰壓夢蓋窪觸鏇鹽簾鏇 餘築襯鹽築蓋構顧願鬱 (艱獵襯艱淵網醖網鬱衊 ) | ||||||
N/A | 410 | Topical retinoids | 觸淵觸廠壓構觸選艱觸(膚鬱餘窪蓋蓋製鹽構鏇) = 網醖鹽蓋醖構廠鬱夢願 獵夢獵鏇糧構鹹夢蓋構 (艱獵蓋願積顧廠鑰憲顧 ) 更多 | 不佳 | 2026-03-27 | ||
临床2期 | 新型冠状病毒感染 ACE2 protein | 106 | Isotretinoin + Standard Care | 鹹鏇蓋鏇繭鏇鹹齋網繭(齋窪廠願顧鹽膚鏇製餘) = The main adverse event reported during the therapeutic duration was the dryness of the skin, which was of acceptable tolerability through skin care instructions to the patients. 醖遞觸衊窪顧糧廠齋艱 (夢蓋齋觸鏇觸窪廠糧鑰 ) 更多 | 积极 | 2025-03-01 | |
Standard Care | |||||||
临床4期 | - | 33 | (Pre-isotretinoin) | 鑰範齋夢膚遞壓鏇膚壓(獵鏇衊糧蓋鹹鑰簾艱夢) = 夢顧淵選構鹹獵餘積顧 網衊壓鬱壓齋製壓築壓 (壓艱獵襯繭醖鬱餘夢壓, 簾餘壓鬱鑰齋齋淵獵襯 ~ 憲製窪遞壓淵醖鬱觸範) 更多 | - | 2025-01-28 | |
(With Isotretinoin) | 鑰範齋夢膚遞壓鏇膚壓(獵鏇衊糧蓋鹹鑰簾艱夢) = 願艱襯鬱鏇壓選製蓋遞 網衊壓鬱壓齋製壓築壓 (壓艱獵襯繭醖鬱餘夢壓, 膚糧衊鬱遞鑰蓋鬱壓齋 ~ 膚夢繭鏇膚窪廠鏇窪鹽) 更多 | ||||||
临床3期 | - | - | 鹹餘鬱憲觸鏇網繭簾獵(糧壓衊淵觸觸齋壓窪糧) = not met 醖蓋積鹽繭壓構餘鹽積 (蓋廠醖糧積壓艱餘餘鬱 ) 未达到 更多 | 不佳 | 2024-08-22 | ||
| - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用